892388-55-5

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 3-[([1,1'-biphenyl]-2-ylmethyl)amino]-, 1,1-dimethylethyl ester, (3S)-
• CAS NO: 892388-55-5
• Molecular Formula: C22H28N2O2
• Molecular Weight: 352.477
• Mol File: 892388-55-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 3-[([1,1'-biphenyl]-2-ylmethyl)amino]-, 1,1-dimethylethyl ester, (3S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 3-[([1,1'-biphenyl]-2-ylmethyl)amino]-, 1,1-dimethylethyl ester, (3S)-(892388-55-5)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 3-[([1,1'-biphenyl]-2-ylmethyl)amino]-, 1,1-dimethylethyl ester, (3S)-(892388-55-5)

Safety Data

• Hazardous Substances Data: 892388-55-5(Hazardous Substances Data)

Upstream product

• 1203-68-5 2-Phenylbenzaldehyde 
• 147081-44-5 (3S)-3-amino-1-(tert-butoxycarbonyl)-pyrrolidine 

Downstream Products

• 929541-67-3 (S)-3-(biphenyl-2-ylmethyl-ethyl-amino)-pyrrolidine-1-carboxylic-acid tert-butyl ester 
• 1049777-81-2 C₂₃H₂₇ClN₂O₃ 
• 1049777-19-6 (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine 
• 892388-56-6 tert-butyl (3S)-3-[(biphenyl-2-ylmethyl)(isobutyryl)amino]pyrrolidine-1-carboxylate 

Relevant articles and documents

N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors

The structure-activity relationship and the synthesis of novel N-benzyl-N-(pyrrolidin-3-yl)carboxamides as dual serotonin (5-HT) and noradrenaline (NA) monoamine reuptake inhibitors are described. Compounds such as 18 exhibited dual 5-HT and NA reuptake i

THERAPEUTIC PYRROLIDINES

The present invention provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I) or pharmaceutically acceptable salts thereof.